# a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy

Source: https://onco.cc/trials/nct06789796/  
OnCo record `nct06789796` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Iparomlimab and tuvonralimab in Small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy is a phase 3 interventional study registered as NCT06789796 by Qilu Pharmaceutical Co., Ltd., with 636 participants planned, started 2025-02 and due to reach its primary completion in 2028-03. Interventions recorded: Iparomlimab and Tuvonralimab (QL1706), placebo for QL1604, QL1604, placebo for Iparomlimab and Tuvonralimab (QL1706). Conditions recorded: Small-cell Lung Cancer.

Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06789796
- Phase: 3
- Setting: A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 636

## Sources

- ClinicalTrials.gov NCT06789796: https://clinicaltrials.gov/study/NCT06789796

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06789796.json